Bone marrow-derived mesenchymal stem cells for treatment of poor graft function

The aim of this study is to evaluate the efficacy and safety of expanded allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) in treating patients with poor graft function (PGF) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Preliminary results indicate that allogeneic BM-MSCs effectively treat both primary and secondary post-allo-HSCT PGF. 17 of 20 patients undergoing allo-HSCT with PGF were responsive to MSC treatment. No patient experienced any acute toxicity following BM-MSC treatment and in most patients, no secondary tumors were detected.